Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities
Invitae and KEW announced a collaboration to develop comprehensive genomic profiling solutions for sequencing tumor DNA on Invitae's next generation sequencing platform. Invitae will fund the collaborative development efforts to integrate KEW's technology into its platform and workflow. March 16, 2018